ATRX and Familial prostate cancer: Although prognostic alterations in CRC, breast cancer, cholangiocarcinoma, melanoma, and head and neck squamous carcinoma are also predictive for benefit from targeted therapies, alterations in NSCLC (activating KRAS mutations, 18.4%), prostate cancer (alterations in at least 2 of PTEN, RB1, and TP53, 20.4%), glioma (TERT promoter 56.1%, TP53 44.9%, IDH1 19.0%, ATRX 16.1%, H3F3A 4.3%, IDH2 0.2%), or uveal melanoma (BAP1 59.2%, SF3B1 23.9%) are specifically prognostic.